Kybella is approved only to melt fat under the chin. The FDA is warning that using it elsewhere on the body — an increasingly popular cosmetic trend — has caused serious adverse reactions.
A detailed look inside the aging hippocampus reveals that brain aging isn’t a slow, steady slide — it’s a coordinated overhaul of the brain’s immune and blood-vessel systems that peaks in a specific midlife-to-later-life window.
GSK is paying up to $750 million for global rights to Chimagen’s trispecific T-cell engager for multiple myeloma — the latest sign of the company rebuilding the oncology franchise it sold off a decade ago.
Curium’s Bexlutry, a generic of Novartis’s Lutathera, is the first “radioligand equivalent” approved in the U.S. — a milestone that could open a fast-growing but supply-constrained corner of cancer care to competition.
In its final Phase 3 analysis, Trutakna (atacicept) essentially stabilized kidney function and cut disease-progression events by 76% in IgA nephropathy — strong data as Vera pushes for full FDA approval.
Pooling 139 trials, researchers found the most effective drug-free treatments for knee osteoarthritis were surprisingly simple: knee braces, water-based therapy and regular exercise — while a common clinic staple ranked near the bottom.
Definium’s DT120 eased generalized anxiety in a second large Phase 3 study — positioning the company to seek what would be the first-ever approval of a psychedelic medicine for anxiety.
Breast cancer patients with vitamin D deficiency needed more pain medicine and reported more moderate pain after mastectomy — a suggestive link, though the study can’t prove cause and effect.
Up to 1 in 5 people with high blood pressure may have a hormone disorder that standard daytime blood tests overlook — because the telltale hormone surges mostly at night.
A pioneer of donor-derived cell therapy is walking away from cancer CAR-T — battered by competition — and pivoting to in vivo gene editing for heart disease. Investors sent the stock down 43%.
A red-light photodynamic treatment with Biofrontera’s Ameluz gel is now approved for superficial basal cell carcinoma — the first photodynamic therapy okayed for any skin cancer.
Wall-mounted sensors processing on-device rather than in the cloud. The architecture choice is what makes the product legally and practically deployable.